ANI Pharmaceuticals (ANIP) Q1 2024 Earnings
ANIP·Reported May 10, 2024·Before market open
ANI Pharmaceuticals reported Q1 2024 revenue of $137.4M, beat analyst consensus of $125.5M by $11.9M. Diluted EPS came in at $1.21, beat the $0.98 consensus by $0.23.
Revenue
$137.4Mbeat by $11.9M
Consensus: $125.5MDiluted EPS
$1.21beat by $0.23
Consensus: $0.98
Financial Snapshot
Trailing eight quarters through Q1 2024
Q1 2024 Earnings FAQ
Common questions about ANI Pharmaceuticals's Q1 2024 earnings report.
ANI Pharmaceuticals (ANIP) reported Q1 2024 earnings on May 10, 2024 before market open.
ANI Pharmaceuticals reported revenue of $137.4M and diluted EPS of $1.21 for Q1 2024.
Revenue beat the consensus estimate of $125.5M by $11.9M. EPS beat the consensus estimate of $0.98 by $0.23.
You can read the 10-Q periodic report (0001023024-24-000057) directly on SEC EDGAR. The filing index links above go to sec.gov.